title: NK activity during graft-versus-host disease and graft rejection in rats following intestinal semiallogenic and allogenic transplantation with or without mesenteric lymphadenectomy.
abstract: Graft-versus-host disease (GVHD) and graft rejection are major problems following intestinal transplantation (IT). Natural killer (NK) cells may be important effector cells in both conditions. In this study, Sprague-Dawley (SD) or SD-Brown Norway (BN) F1 rat intestine was transplanted into BN recipients with and without associated graft mesenteric lymphadenectomy (GML). Cyclosporine (15 mg/kg day) was administered to all animals. Pieces of the intestinal graft were examined 4 days posttransplant and again at death. NK activity calculated using intestinal intraepithelial lymphocytes (IL) was determined utilizing an 18-hr cytotoxic assay assessing 51Cr release and the results are reported as lytic units. YAC-1 cells were used as the target. NK activity was reduced 4 days after IT both in native (8.02 +/- 0.64) and in grafted bowel (3.14 +/- 1.51), with histological evidence of rejection as compared with that of control bowel in ungrafted rats (21.1 +/- 2.14). Survival was increased, on mean, a total of 6 days with the addition of GML in both semiallogenic and allogenic transplanted rats. At the time of death, the NK activity in the native bowel had increased (17.1 +/- 3.02) and histologic evidence of GVHD was present. These data suggest that: (1) NK cells are important in GVHD and (2) both semiallogenic and allogenic transplants survive longer if they are combined with GML (P < or = 0.05 and P < or = 0.01, respectively).
authors.affiliation: Department of Surgery, University of Padua Medical Center, Oklahoma City, Oklahoma.
authors.forename: E E
authors.initials: EE
authors.lastname: Frezza
authors.forename: G E
authors.initials: GE
authors.lastname: Gerunda
authors.forename: A
authors.initials: A
authors.lastname: Fassina
authors.forename: R
authors.initials: R
authors.lastname: DeFranchis
authors.forename: R
authors.initials: R
authors.lastname: Biffi
authors.forename: A
authors.initials: A
authors.lastname: Gurakar
authors.forename: S
authors.initials: S
authors.lastname: Fagiuoli
authors.forename: A M
authors.initials: AM
authors.lastname: Faccioli
authors.forename: D H
authors.initials: DH
authors.lastname: Van Thiel
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage; D003602:Cytotoxicity, Immunologic; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology*; D006086:Graft vs Host Disease / Q000276:immunology*; D007421:Intestine, Small / Q000166:cytology / Q000637:transplantation*; D007694:Killer Cells, Natural / Q000276:immunology*; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000276:immunology*; D008643:Mesentery; D051381:Rats; D011914:Rats, Inbred BN; D017207:Rats, Sprague-Dawley; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D016572:Cyclosporine